{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "document_type": "blogpost", "multimedia": [], "abstract": "The Swiss pharmaceutical giant Roche will pay more than $1 billion in a deal aimed at improving both cancer treatment and drug development.", "type_of_material": "Blog", "word_count": "810", "lead_paragraph": null, "pub_date": "2015-01-12T01:01:21Z", "_id": "54b3638738f0d82eb90f0fff", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "source": "The New York Times", "snippet": "The Swiss pharmaceutical giant Roche will pay more than $1 billion in a deal aimed at improving both cancer treatment and drug development.", "web_url": "http://dealbook.nytimes.com/2015/01/12/roche-to-buy-majority-stake-in-foundation-medicine-leader-in-tumor-testing/", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "value": "Foundation Medicine Inc", "name": "organizations"}, {"rank": "2", "value": "Roche Holding AG", "name": "organizations"}, {"rank": "1", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "headline": {"main": "Roche to Buy Majority Stake in Foundation Medicine, Leader in Tumor Testing", "kicker": "DealBook"}}